| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| T412004-100μg | 100μg | In stock | $39.90 | |
| T412004-1mg | 1mg | In stock | $159.90 | |
| T412004-5mg | 5mg | In stock | $664.90 | |
| T412004-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,196.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Tocilizumab (anti-IL-6R), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL-6Ra/CD126, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Q369O8926L | CHEBI:27881 | CU-01000001503-3 | HMS1792H15 | NSC133100 | BPBio1_000479 | NCGC00344093-09 | RESVERATROL (MART.) | MLS000069735 | MLS001076538 | Stilbene, 2f | (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol | MLS002222231 | TaxusChinensisi |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | IL-6Ra/CD126 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of Interleukin-6 receptor |
| Product Description | Tocilizumab is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab can be used for the treatment of rheumatoid arthritis. It is remarkablely effective for the study of severe COVID-19 (coronavirus disease). |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 26.6 kDa (Light Chain) & 51.4 kDa (Heavy Chain), under reducing conditions; 174.3 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 375823-41-9 |
Tocilizumab (anti-IL-6R) (T412004) - ELISA
Immobilized Recombinant Human IL-6R Protein at 2 μg/mL can bind Tocilizumab (anti-IL-6R) (T412004) with the EC₅₀ of 5.8 ng/mL.
Tocilizumab (anti-IL-6R) (T412004) - SEC
The purity of Tocilizumab (anti-IL-6R) (T412004) is more than 95% verified by HPLC.
Tocilizumab (anti-IL-6R) (T412004) - ELISA
Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 1.0 μg/mL can bind Tocilizumab (anti-IL-6R) (T412004) with the EC50 of 21.05 ng/mL.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 96 |
|---|---|
| Wikipedia | Tocilizumab |
| PEP | tocilizumab |
| Immunopaedia Search | tocilizumab |
| Reactome Reaction | R-HSA-9681294 |
| Reactome Drug | R-ALL-9681301 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0404271 | Certificate of Analysis | Apr 10, 2024 | T412004 |
| ZJ24F0404272 | Certificate of Analysis | Apr 10, 2024 | T412004 |
| ZJ24F0404270 | Certificate of Analysis | Apr 10, 2024 | T412004 |
| 1. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J et al.. (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.. Arthritis Rheum, 54 (9): (2817-29). [PMID:16947782] [10.1021/op500134e] |
| 2. Paul-Pletzer K. (2006) Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.. Drugs Today, 42 (9): (559-76). [PMID:17028666] [10.1021/op500134e] |
| 3. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. (2007) Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.. Intern Med, 46 (11): (771-4). [PMID:17541233] [10.1021/op500134e] |
| 4. Nishimoto N, Kishimoto T. (2008) Humanized antihuman IL-6 receptor antibody, tocilizumab.. Handb Exp Pharmacol, 71 (181): (151-60). [PMID:18071945] [10.1021/op500134e] |
| 5. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.. Int Immunopharmacol, 5 (12): (1731-40). [PMID:16102523] [10.1021/op500134e] |
| 6. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. (2005) Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.. Clin Rev Allergy Immunol, 28 (3): (231-8). [PMID:16129907] [10.1021/op500134e] |
| 7. Ohsugi Y, Kishimoto T. (2008) The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis.. Expert Opin Biol Ther, 8 (5): (669-81). [PMID:18407769] [10.1021/op500134e] |
| 8. Unizony S, Kermani TA. (2018) IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis.. J Neuroophthalmol, 38 (4): (551-558). [PMID:30199509] [10.1021/op500134e] |
| 9. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J et al.. (2021) Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.. JAMA Intern Med, 181 (1): (41-51). [PMID:33080002] [10.1021/op500134e] |
| 10. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C et al.. (2021) Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.. JAMA Intern Med, 181 (1): (24-31). [PMID:33080005] [10.1021/op500134e] |
| 11. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, CORIMUNO-19 Collaborative Group. (2021) Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.. JAMA Intern Med, 181 (1): (32-40). [PMID:33080017] [10.1021/op500134e] |
| 12. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM et al.. (2020) Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.. N Engl J Med, 383 (24): (2333-2344). [PMID:33085857] [10.1021/op500134e] |
| 13. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B et al.. (2020) Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019.. Clin Infect Dis, 71 (8): (1937-1942). [PMID:32301997] [10.1021/op500134e] |
| 14. Wang W, Liu X, Wu S, Chen S, Li Y, Nong L, Lie P, Huang L, Cheng L, Lin Y et al.. (2020) Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics.. J Infect Dis, 222 (9): (1444-1451). [PMID:32601708] [10.1021/op500134e] |
| 15. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] [10.1021/op500134e] |
| 16. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039] [10.1021/op500134e] |
| 17. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, Ivancic N, Branson KM, Hall NE, Simpson RJ. (2002) Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.. Proc Natl Acad Sci USA, 99 (25): (15959-64). [PMID:12461182] [10.1021/op500134e] |
| 18. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785] [10.1021/op500134e] |
| 19. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al.. (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.. Arthritis Res Ther, 17 (13): (135). [PMID:25994180] [10.1021/op500134e] |
| 20. Kang S, Tanaka T, Narazaki M, Kishimoto T. (2019) Targeting Interleukin-6 Signaling in Clinic.. Immunity, 50 (4): (1007-1023). [PMID:30995492] [10.1016/j.immuni.2019.03.026] |
| 21. Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, Li C.. (2014) Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.. J Med Chem, 57 (3): (632-641). [PMID:24456369] [10.1021/jm401144z] |
| 22. Schooltink, H H and 7 more authors.. (1991) Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells.. The Biochemical journal, (1): [PMID:1872801] |
| 23. Novick, D D, Engelmann, H H, Wallach, D D and Rubinstein, M M.. (1989) Soluble cytokine receptors are present in normal human urine.. The Journal of experimental medicine, (1): [PMID:2529343] |
| 24. Yamasaki, K K and 8 more authors.. (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.. Science (New York, N.Y.), (12): [PMID:3136546] |
| 25. Horiuchi, S S and 8 more authors.. (1994) Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism.. European journal of immunology, [PMID:8056053] |
| 26. Yawata, H H and 7 more authors.. (1993) Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130.. The EMBO journal, [PMID:8467812] |
| 27. Cole, A R AR and 6 more authors.. (1999) Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor.. The Journal of biological chemistry, (12): [PMID:10066782] |
| 28. Martens, A S AS, Bode, J G JG, Heinrich, P C PC and Graeve, L L.. (2000) The cytoplasmic domain of the interleukin-6 receptor gp80 mediates its basolateral sorting in polarized madin-darby canine kidney cells.. Journal of cell science, [PMID:11017875] |
| 29. Nakahara, Hideko H and 6 more authors.. (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.. Arthritis and rheumatism, [PMID:12794819] |
| 30. Buk, Deborah M DM, Renner, Olga O and Graeve, Lutz L.. (2005) Increased association with detergent-resistant membranes/lipid rafts of apically targeted mutants of the interleukin-6 receptor gp80.. European journal of cell biology, [PMID:16270750] |
| 31. Gregory, S G SG and 178 more authors.. (2006) The DNA sequence and biological annotation of human chromosome 1.. Nature, (18): [PMID:16710414] |
| 32. Smolen, Josef S JS and Maini, Ravinder N RN.. (2006) Interleukin-6: a new therapeutic target.. Arthritis research & therapy, [PMID:16899109] |
| 33. Reich, David D and 23 more authors.. (2007) Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels.. American journal of human genetics, [PMID:17357077] |
| 34. Betts, Brian C BC, St Angelo, Erin T ET, Kennedy, Michael M and Young, James W JW.. (2011) Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.. Blood, (10): [PMID:21940820] |
| 35. Huizinga, Tom W J TW and 9 more authors.. (2014) Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.. Annals of the rheumatic diseases, [PMID:24297381] |
| 36. and Lin, Phoebe P.. (2015) Targeting interleukin-6 for noninfectious uveitis.. Clinical ophthalmology (Auckland, N.Z.), [PMID:26392750] |
| 37. Lokau, Juliane J and 13 more authors.. (2016) Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.. Cell reports, (23): [PMID:26876177] |
| 38. June, Rayford R RR and Olsen, Nancy J NJ.. (2016) Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.. Expert opinion on biological therapy, [PMID:27464017] |
| 39. Riethmueller, Steffen S and 23 more authors.. (2017) Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation.. PLoS biology, [PMID:28060820] |
| 40. Smolen, Josef S JS and 48 more authors.. (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.. Annals of the rheumatic diseases, [PMID:28264816] |
| 41. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM.. (2017) SorLA in Interleukin-6 Signaling and Turnover.. Molecular and cellular biology, (1): [PMID:28265003] |
| 42. Kampan, Nirmala Chandralega NC and 5 more authors.. (2018) Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.. Current medicinal chemistry, [PMID:28707587] |
| 43. Spencer, Sarah and 37 more authors.. (2019) Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses.. The Journal of experimental medicine, (2): [PMID:31235509] |
